Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
Apr 15, 2010 (Vol. 30, No. 8)

Request for Proposals for Better Multiple Sclerosis Therapies

  • EMD Serono and Fast Forward put out a request for proposals (RFPs) from academic groups and emerging biotech and pharmaceutical firms involved in multiple sclerosis R&D programs. RFPs are being accepted now through the EMD Serono Collaborative Fund for projects in the following target areas: therapeutic strategies to modulate the innate immune system in the CNS, and therapeutic strategies to promote axonal protection, restoration, and function through CNS-targeted mechanisms including modulation of CNS ion channels. Applications will be considered until June 1, 2010.

    For more information and to apply for the RFP please visit www.fastforward.org.

    For investigators and companies interested in learning more about this RFP and program, there will be a live teleconference April 23. Email: [email protected] for details.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »